本帖最后由 老马 于 2012-1-13 21:20 编辑 - H' T4 U: V( c# ^- y ~
. | \0 Y4 y8 S5 o7 S2 p9 Z: O
爱必妥和阿瓦斯丁的比较. ?: ]. g1 {6 c- d# p2 y- E
. \/ k. A1 ~! @4 K
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/5 ?5 W" ?! }$ `0 u, F1 |) a K
3 S+ L6 V. s8 O" M3 @ c
" u3 W- ?9 I" j2 q$ o9 r" \
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
' g! S7 L# b; c# |, Z==================================================
7 y" [/ @3 Y4 q0 Q* g# C, Q" w. h$ WOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
|+ h( R$ l6 u6 b. n& c/ ?Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
- Y: t$ p' G( l+ e: bResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
3 X2 b7 N$ I; M- K7 d# l' k
|